Survey notes increase of orphan-drug designations by the FDA

01/20/2010 | MSNBC

A survey by Tufts University found that the number of treatments that received orphan-drug designation from the FDA increased from 208 products between 2000 and 2002 to 425 between 2006 and 2008. The data highlight pharmaceutical companies' growing interest in drugs for rare diseases, according to the study.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX